Drugs by Condition

Chronic Lymphocytic Leukemia Medications

Drugs (by generic name) associated with Chronic Lymphocytic Leukemia

The following drugs and medications are in some way related to, or used in the treatment of Chronic Lymphocytic Leukemia. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

Drug Name ( View by: Brand \| Generic )	Reviews	Ratings
chlorambucil systemic (Pro, More...) class: alkylating agents	2 review(s)	Rate It!	9.5
fludarabine systemic (Pro, More...) class: antimetabolites	1 review(s)	Rate It!	6.0
rituximab systemic (Pro, More...) class: antineoplastic monoclonal antibodies, antirheumatics, CD20 monoclonal antibodies, tyrosine kinase inhibitors	0 review(s)	Not rated - Be the first
immune globulin intravenous systemic (Pro, More...) class: immune globulins	0 review(s)	Not rated - Be the first
bendamustine systemic (Pro, More...) class: alkylating agents	0 review(s)	Not rated - Be the first
cyclophosphamide systemic (Pro, More...) class: alkylating agents	0 review(s)	Not rated - Be the first
alemtuzumab systemic (Pro, More...) class: antineoplastic monoclonal antibodies, CD52 monoclonal antibodies, monoclonal antibodies, tyrosine kinase inhibitors	0 review(s)	Not rated - Be the first

Chronic Lymphocytic Leukemia Medications in the Pipeline

Genasense (oblimersen sodium)

March 9, 2009 - FDA Appeal Decision Indicates that Genasense Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Trial
December 12, 2008 - Genta to Appeal FDA Decision on New Drug Application for Genasense in Patients with Chronic Lymphocytic Leukemia
December 3, 2008 - Genta Receives Complete Response Letter from FDA to Amended Application of Genasense in Patients with Chronic Lymphocytic Leukemia
July 14, 2008 - FDA Accepts Genta's NDA Amendment as Complete Response for Genasense Treatment of Chronic Lymphocytic Leukemia
June 6, 2008 - Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia
March 17, 2008 - FDA Indicates That Genasense Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data
January 14, 2008 - FDA Extends Review of Genasense NDA Appeal in Chronic Lymphocytic Leukemia
October 25, 2007 - Genta Completes Appeal of FDA Decision for Genasense in CLL
April 4, 2007 - Genta Appeals FDA Decision on Genasense in CLL
February 6, 2007 - Genta Announces the Company Will Appeal FDA Action on New Drug Application of Genasense in Chronic Lymphocytic Leukemia
December 15, 2006 - Genta Receives Non-Approvable Notice for Application of Genasense in Patients With Chronic Lymphocytic Leukemia
October 30, 2006 - FDA Extends Review Period for Genasense New Drug Application in Chronic Lymphocytic Leukemia
September 5, 2006 - Briefing Documents Posted for FDA Committee Review of Genasense New Drug Application
July 27, 2006 - Genta Announces FDA's Oncology Drug Advisory Committee Will Review Genasense as Treatment for Chronic Lymphocytic Leukemia
March 1, 2006 - Genasense New Drug Application Accepted for Review by FDA
December 29, 2005 - Genta Files New Drug Application for FDA Approval of Genasense Plus Chemotherapy for Patients with Advanced or Refractory Chronic Lymphocytic Leukemia
June 30, 2005 - Genta Initiates New Drug Application for Genasense in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
May 13, 2004 - Genta Announces Withdrawal of New Drug Application for Genasense in Melanoma
May 3, 2004 - FDA Advisory Committee Reviews Genasense For Use in Advanced Melanoma
April 20, 2004 - Genta and Aventis Announce Genasense Expanded Access Program for Patients with Advanced Melanoma
February 6, 2004 - Aventis and Genta Announce FDA Acceptance and Priority Review of New Drug Application for Genasense in Advanced Melanoma

Latest Chronic Lymphocytic Leukemia Blog Post

Memgen Reports Positive Results for ISF35 in High-Risk Chronic Lymphocytic Leukemia
DALLAS--(BUSINESS WIRE)--Jun 4, 2009 - Memgen announced today that the ongoing Phase Ib study of its cancer immune therapy, ISF35, has produced positive results, including a complete remission in the trial's first patient who had 17p deleted chronic lymphocytic...

View all Chronic Lymphocytic Leukemia blog posts.